Relapsed or Refractory Multiple Myeloma (RRMM) Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting relapsed or refractory multiple myeloma (rrmm) clinical trials across 32 countries. Studies span Phase 1, Phase 3, Not Applicable, Phase 2. Top locations include Shanghai, China, Adelaide, South Australia, Australia, Amsterdam, North Holland, Netherlands. Updated daily from ClinicalTrials.gov.


Relapsed or Refractory Multiple Myeloma (RRMM) Trials at a Glance

6 actively recruiting trials for relapsed or refractory multiple myeloma (rrmm) are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Shanghai, Adelaide, and Amsterdam. Lead sponsors running relapsed or refractory multiple myeloma (rrmm) studies include Beijing GoBroad Hospital, Anhui Provincial Hospital, and Chengdu Zenitar Biomedical Technology Co., Ltd.

Browse relapsed or refractory multiple myeloma (rrmm) trials by phase

Treatments under study

About Relapsed or Refractory Multiple Myeloma (RRMM) Clinical Trials

Looking for clinical trials for Relapsed or Refractory Multiple Myeloma (RRMM)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed or Refractory Multiple Myeloma (RRMM) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled140 locationsNCT06615479
Recruiting
Phase 3

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (RRMM)
Shandong New Time Pharmaceutical Co., LTD261 enrolled1 locationNCT07579234
Recruiting
Phase 1

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003568
Recruiting
Phase 1

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Relapsed or Refractory Multiple Myeloma (RRMM)
Beijing GoBroad Hospital18 enrolled1 locationNCT07003555
Recruiting
Not Applicable

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital18 enrolled1 locationNCT06961669
Recruiting
Phase 1Phase 2

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd144 enrolled1 locationNCT06484829